NCT06326060Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

Name: Clinical Trial NCT06326060
Creator: Novo Nordisk A/S
Keywords: Obesity, NNC0519-0130, Phase 2, drug, clinical trial, Australia,Japan,United States of America

Investigation of the Safety and Efficacy of Once Weekly NNC0519-0130 in Participants With Overweight or Obesity - a Dose Finding Study

Novo Nordisk A/SPhase 2ClinicalTrials.govdrug

Verified

Study focus

Disease/Condition: Obesity
Drug/Device/Intervention: NNC0519-0130
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Novo Nordisk A/S
Location: Mesa,Little Rock,Searcy,Costa Mesa,Walnut Creek,Aurora,Crystal River,Fleming Island,Jacksonville,Chicago,Indianapolis,Valparaiso,Louisville,Columbia,Saint Peters,New York,Greensboro,Greensboro,Greenvi, Australia,Japan,United States of America

Timeline & enrollment

Phase: Phase 2
Start date: Mar 18, 2024
End date: May 05, 2025
Enrollment: 343 participants

Primary outcome

Relative change in body weight

Summary

This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 42 weeks.

ICD-10 classifications

ObesityOther obesityObesity, unspecifiedObesity due to excess caloriesObesity and other hyperalimentation

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06326060
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06326060 through Pure Global AI's free database. This Phase 2 trial is sponsored by Novo Nordisk A/S and is currently Recruiting. The study focuses on Obesity. Target enrollment is 343 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.